Search company, investor...
Cellectar company logo

Cellectar

cellectar.com

Founded Year

2003

Stage

Acquired | Acquired

Total Raised

$15.72M

About Cellectar

Cellectar is a radiopharmaceuticals company that designs, develops, and manufactures products to detect, treat and monitor a wide variety of human cancers. Their product candidates combine lipid-like molecules, phospholipid ethers (PLEs), with radioisotopes that destroy malignant cells.

Headquarters Location

100 Campus Dr Suite 207

Florham Park, New Jersey, 07932,

United States

608-441-8120

Missing: Cellectar's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cellectar's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cellectar

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cellectar is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Cellectar Patents

Cellectar has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/15/2016

6/26/2018

Radiation therapy, Stem cells, Medical physics, Transcription factors, Oncology

Grant

Application Date

4/15/2016

Grant Date

6/26/2018

Title

Related Topics

Radiation therapy, Stem cells, Medical physics, Transcription factors, Oncology

Status

Grant

Latest Cellectar News

In the clinic for Sept. 23, 2021

Sep 23, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Betterlife, Cassava Sciences, Cellectar, Clover, Codagenix, Corvus, Endeavor Biomedicines, Enlivex, Frequency, Gilead Sciences, Humanetics, Huyabio International, Kintara, Noxxon, Odyssey Group International, Onconova, Phoxbio, Rhizen, Rhythm, Tarsier, Theratechnologies.

Cellectar Frequently Asked Questions (FAQ)

  • When was Cellectar founded?

    Cellectar was founded in 2003.

  • Where is Cellectar's headquarters?

    Cellectar's headquarters is located at 100 Campus Dr, Florham Park.

  • What is Cellectar's latest funding round?

    Cellectar's latest funding round is Acquired.

  • How much did Cellectar raise?

    Cellectar raised a total of $15.72M.

  • Who are the investors of Cellectar?

    Investors of Cellectar include Cellectar Biosciences, Advantage Capital and Venture Investors.

  • Who are Cellectar's competitors?

    Competitors of Cellectar include CoImmune, Banyan Biomarkers, Stemina Biomarker Discovery, Esperance Pharmaceuticals, Endocare and 13 more.

Compare Cellectar to Competitors

ReproCELL Logo
ReproCELL

ReproCell is a developer of stem cell technologies. The company develops various products, with an underlying theme that focuses on stem cell technology, to address the needs of researchers and clinicians. The product range encompasses reagents for ES/iPS cells and stem cell-derived functional cells.

Stemina Biomarker Discovery Logo
Stemina Biomarker Discovery

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

B
BresaGen

NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.

Regenetech Logo
Regenetech

Regenetech develops and offers intellectual property licenses in the area of Adult Stem Cell Expansion and therapeutic applications of adult stem cells. Regenetech uses a technology discovered by NASA in space experiments for growing three-dimensional (3D) stem cells in a weightless environment.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.